title: The role of the matrix metalloproteinases during in vitro vessel formation.
abstract: Matrix metalloproteinases (MMPs) constitute a large family of extracellular matrix degrading proteases implicated in a number of physiological and pathological processes, including angiogenesis. However, the relative importance of the individual MMPs in vessel formation is poorly understood. Using the three-dimensional rat aortic model, the role of the MMPs in angiogenesis in vitro was investigated both by the use of synthetic MMP inhibitors, and by a study of the expression of nine MMPs and three of their endogenous inhibitors (the TIMPs) during vessel formation. Inhibition of microvessel growth in this model by the MMP inhibitor Marimastat demonstrated the requirement of the MMPs for angiogenesis in both collagen and fibrin matrices (half-maximal inhibition at 5 and 80 nM, respectively). The profile of MMP expression was seen to be modified by both matrix composition and exogenous growth factors. For example, whilst the gelatinase MMP-2 and stromelysin MMP-3 were present at high levels in fibrin culture, the stromelysin MMP-11 and membrane-type-1-MMP were more highly expressed during vessel formation in collagen. The angiogenic basic fibroblast growth factor (bFGF) upregulated the expression of the gelatinases (MMP-2 and MMP-9), the stromelysins (MMP-3, MMP-10 and MMP-11) and the interstitial collagenase MMP-13, whereas vascular endothelial growth factor (VEGF) led to a marked increase in expression of MMP-2 only. Together, the environment-dependent upregulation in expression of a number of MMPs during angiogenesis, and the total inhibition of vessel growth observed at nanomolar concentrations of synthetic MMP inhibitors, suggests a major collective role of these enzymes in angiogenesis, and provides a basis for further development of MMP inhibitors for anti-angiogenic therapy.
authors.affiliation: Division de Cancérologie Expérimentale, Institut de Recherches Servier, Croissy sur Seine, France. mike.burbridge@fr.netgrs.com
authors.forename: M F
authors.initials: MF
authors.lastname: Burbridge
authors.forename: F
authors.initials: F
authors.lastname: Cogé
authors.forename: J P
authors.initials: JP
authors.lastname: Galizzi
authors.forename: J A
authors.initials: JA
authors.lastname: Boutin
authors.forename: D C
authors.initials: DC
authors.lastname: West
authors.forename: G C
authors.initials: GC
authors.lastname: Tucker
mesh_terms: D000818:Animals; D001011:Aorta; D001013:Aorta, Thoracic / Q000166:cytology; D001483:Base Sequence; D002478:Cells, Cultured; D003094:Collagen / Q000502:physiology; D017931:DNA Primers; D005109:Extracellular Matrix / Q000201:enzymology; D006801:Humans; D008297:Male; D020782:Matrix Metalloproteinases / Q000235:genetics* / Q000378:metabolism*; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D009389:Neovascularization, Pathologic / Q000473:pathology*; D018919:Neovascularization, Physiologic / Q000502:physiology*; D016133:Polymerase Chain Reaction; D051381:Rats; D011916:Rats, Inbred F344; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism
chemical_list: D017931:DNA Primers; D019714:Tissue Inhibitor of Metalloproteinases; D003094:Collagen; D020782:Matrix Metalloproteinases